Artimplant: Artelon® STT Spacer Receives Regulatory Clearance for Marketing in the USA
The Göteborg based biomaterials company Artimplant receives regulatory clearance for marketing Artelon® STT Spacer in the USA. The product is indicated for osteoarthritis in the STT joint. Small Bone Innovations, the licensee of Artimplant, now gets the opportunity to market the product at its domestic market USA.
Patients in the USA with osteoarthritis in both the CMC and STT joints that previously could not be treated for thumb base osteoarthritis with only Artelon® CMC Spacer will as of now have the possibility to benefit from Artimplant´s Artelon® Spacers in both joints.Says President and CEO Hans Rosén:
“Artelon® STT Spacer is an important complement to our currently best selling product Artelon® CMC Spacer. In addition each new Artelon® product that receives regulatory clearance increases market awareness of the unique capacity of Artelon® in various medical applications."
Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral applications. Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.
